Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTK Inhibitors vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia / Lymphoplasmacytic Lymphoma
NCT04840602Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2022
- Primary completion
- Mar 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in Waldenstrom macroglobulinemia (WM), Lymphoplasmacytic Lymphoma (LPL), sponsored by National Cancer Institute. Started Jan 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
Waldenstrom macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on NCT04840602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840602.